NewAmsterdam Pharma Company N.V.
NASDAQ Capital MarketTotal Valuation
NewAmsterdam Pharma Company N.V. carries a market capitalization of 3.57B, placing it among publicly traded companies globally. Its enterprise value stands at -636.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.57B |
| Enterprise Value | -636.08M |
Share Statistics
NewAmsterdam Pharma Company N.V. currently has 116.64M shares outstanding.
| Shares Outstanding | 116.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
NewAmsterdam Pharma Company N.V. maintains a current ratio of 9.76, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.76 |
| Quick Ratio | 9.56 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -27.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NewAmsterdam Pharma Company N.V.'s stock has gained approximately 64.21053% over the past 52 weeks. The 50-day moving average sits at 23.07, while the 200-day moving average is 23.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | 64.21053% |
| 50-Day Moving Average | 23.07 |
| 200-Day Moving Average | 23.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -214.95M, while operating income came in at -215.18M.
| Revenue | 22.57M |
| Gross Profit | N/A |
| Operating Income | -215.18M |
| Pretax Income | -212.73M |
| Net Income | -212.73M |
| EBITDA | -214.95M |
| EBIT | -215.18M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
NewAmsterdam Pharma Company N.V. holds 636.11M in cash and equivalents against 23,000.00 in total debt, resulting in a net debt position of -457.61M. Total book value stands at -796.24M, with working capital of 590.62M providing operational flexibility.
| Cash & Cash Equivalents | 636.11M |
| Total Debt | 23,000.00 |
| Net Debt | -457.61M |
| Equity (Book Value) | -796.24M |
| Book Value Per Share | N/A |
| Working Capital | 590.62M |
Cash Flow
NewAmsterdam Pharma Company N.V. produced -141.92M in operating cash flow over the past twelve months.
| Operating Cash Flow | -141.92M |
| Capital Expenditures | -268,000.00 |
| Free Cash Flow | -142.19M |
| FCF Per Share | N/A |
Margins
NewAmsterdam Pharma Company N.V. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -953.59 and net profit margin of -942.76 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -953.59 |
| Pretax Margin | -942.76 |
| Profit Margin | -942.76 |
| EBITDA Margin | -952.57 |
Scores
NewAmsterdam Pharma Company N.V. posts an Altman Z-Score of -1.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.52 |